Wayfinding Financial LLC Invests $238,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Wayfinding Financial LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 2,582 shares of the biopharmaceutical company's stock, valued at approximately $238,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GILD. Bellevue Group AG raised its position in Gilead Sciences by 18.2% in the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company's stock valued at $3,859,000 after buying an additional 7,093 shares during the last quarter. Quantinno Capital Management LP grew its stake in shares of Gilead Sciences by 149.5% during the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company's stock worth $6,843,000 after acquiring an additional 48,910 shares in the last quarter. McAdam LLC raised its holdings in shares of Gilead Sciences by 16.7% in the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock valued at $2,344,000 after purchasing an additional 3,627 shares during the last quarter. Capital Investment Advisors LLC lifted its position in shares of Gilead Sciences by 2.6% in the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company's stock worth $35,793,000 after purchasing an additional 9,791 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in Gilead Sciences by 3.9% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company's stock valued at $13,132,000 after purchasing an additional 5,382 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company's stock, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 302,785 shares of company stock worth $30,503,250. Company insiders own 0.16% of the company's stock.

Gilead Sciences Trading Up 1.3 %

GILD traded up $1.38 during midday trading on Wednesday, hitting $109.27. 7,391,019 shares of the company were exchanged, compared to its average volume of 6,804,936. The firm's 50 day moving average price is $104.35 and its 200-day moving average price is $94.36. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The firm has a market capitalization of $136.08 billion, a P/E ratio of 295.32, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.89%. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's payout ratio is currently 854.05%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on GILD. BMO Capital Markets upped their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. Bank of America raised their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a report on Thursday, February 13th. Oppenheimer upped their price objective on Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a report on Tuesday, March 4th. Finally, The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $104.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.